Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001875620-26-000010
Filing Date
2026-07-07
Accepted
2026-07-07 16:55:19
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 15105
  Complete submission text file 0001875620-26-000010.txt   16886
Mailing Address C/O SANDS CAPITAL ALTERNATIVES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209
Business Address C/O SANDS CAPITAL ALTERNATIVES, LLC 1000 WILSON BOULEVARD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
Sands Capital Life Sciences Pulse Fund II, L.P. (Filed by) CIK: 0001875620 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9
Type: SCHEDULE 13D/A

Mailing Address 47071 BAYSIDE PARKWAY FREMONT CA 94538
Business Address 47071 BAYSIDE PARKWAY FREMONT CA 94538 510-626-9888
Alamar Biosciences, Inc. (Subject) CIK: 0002104204 (see all company filings)

EIN.: 364899036 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-95626 | Film No.: 261159926
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)